Βy Paris Ziogkas, the Co-Founder | CEO at Advantis Medical Imaging
As the ProCAncer-I project reaches its conclusion, we celebrate a collective achievement that stands as a beacon of what European collaboration can deliver at the forefront of medical AI. ProCAncer-I has built one of the world’s largest, most diverse, and FAIR-compliant prostate cancer imaging datasets — ProstateNET — alongside cutting-edge AI models and a robust open platform. These are not abstract academic results: they are concrete Knowledge and Innovation Results (KERs) ready to be exploited for direct societal benefit.
At a time when AI is reshaping industries across the globe, ProCAncer-I places European innovation and values at the heart of this transformation — particularly in healthcare, where trust, transparency, and patient well-being are paramount.
A Rich Portfolio of Exploitable Results
ProCAncer-I delivers a suite of exploitable assets:
👉 AI Models for clinical decision support across the prostate cancer pathway
👉 Software components enabling vendor-neutral, interoperable image processing
👉 A scalable, secure cloud platform for AI development and validation
👉 The unparalleled ProstateNET data repository — a European asset for ongoing AI innovation
These KERs serve multiple domains: clinical use in hospitals, product development by European SMEs, research by academic centers, and integration into wider initiatives like EUCAIM.
Societal, Clinical, and Industrial Impact
The exploitation of ProCAncer-I results comes at a moment of unique societal resonance:
✨ For patients, the validated AI models can enable earlier, more accurate diagnosis, better risk stratification, and more personalized care — reducing overdiagnosis and overtreatment, and improving quality of life across Europe.
✨ For clinicians, AI tools developed in ProCAncer-I offer transparency and trustworthiness — a key step toward routine clinical adoption of AI in radiology.
✨ For the healthcare industry, these assets open new avenues for innovation: European SMEs and medical imaging companies can accelerate product pipelines, leverage vendor-neutral AI, and position themselves strongly in a global AI market dominated by non-EU players.
✨ For European research and innovation, ProstateNET and the platform provide a sustainable foundation for future AI development in cancer and other diseases — helping Europe lead ethically sound, clinically validated AI innovation.
A Timely Contribution to Europe’s AI Landscape
As Europe defines its position in the fast-moving global AI ecosystem, ProCAncer-I exemplifies how public investment and collaborative research can produce ready-to-exploit assets with societal value.
By bringing AI closer to safe, trustworthy clinical use, the project contributes to the ambitions of the European Health Data Space, the EU AI Act, and Europe’s vision of sovereign, human-centric AI.
Toward Expansion and New Horizons
The journey of ProCAncer-I is not an endpoint — it is a catalyst. The assets generated are fertile ground for:
🚀 The creation of new AI models and services in oncology and beyond
🚀 European SME growth and international competitiveness
🚀 Deeper integration with the EUCAIM infrastructure
🚀 Cross-border, cross-disease AI research building on the ProstateNET foundation
AI is at a pivotal moment in our society
ProCAncer-I proudly demonstrates that Europe can lead — not by replicating hype, but by building robust, trusted, and clinically valuable AI for the benefit of patients, clinicians, and our innovation ecosystem.
The seeds planted by this project will continue to grow, driving new advances and ensuring that European AI serves its citizens — with excellence, responsibility, and lasting impact.
